Evaluation of the therapeutic efficacy of different doses of LT4 in pregnant women with high-normal TSH levels and TPOAb positivity in the first half of pregnancy
Background The objective was to investigate the efficacy of different doses of levothyroxine therapy among pregnant women exhibiting high-normal thyroid stimulating hormone levels and positive thyroid peroxidase antibodies throughout the first half of pregnancy. Methods Pregnant women exhibiting high-normal thyroid stimulating hormone levels and thyroid peroxidase antibodies positivity throughout the initial half of pregnancy were selected from January 2021 to September 2023. Based on the different doses of levothyroxine, the pregnant women were categorized into the nonintervention group ($ G_{0} $, 122 women), 25 µg levothyroxine intervention group ($ G_{25} $, 69 women), and 50 µg levothyroxine intervention group ($ G_{50} $, 58 women). Serum parameters, gastrointestinal symptoms, small intestinal bacterial overgrowth (SIBO), maternal and neonatal outcomes were compared after the intervention among the three groups. Results After the intervention, in the $ G_{25} $ and $ G_{50} $ groups, the thyroid stimulating hormone, triglyceride and low-density lipoprotein levels were notably less in contrast to those in the $ G_{0} $ group (P < 0.05). The rates of abdominal distension and SIBO in the $ G_{25} $ and $ G_{50} $ groups were notably lower in contrast to the $ G_{0} $ group (P = 0.043 and 0.040, respectively). The $ G_{50} $ group had a lower rate of spontaneous abortion and premature membrane rupture than the $ G_{0} $ group (P = 0.01 and 0.015, respectively). Before $ 11^{+ 2} $ weeks of gestation and at thyroid peroxidase antibodies levels ≥ 117 IU/mL, in contrast to the $ G_{0} $ group, the $ G_{50} $ group experienced a decreased rate of spontaneous abortion (P = 0.008). The $ G_{50} $ group had significantly higher newborn weight than the $ G_{0} $ group (P = 0.014), as well as a notably longer newborn length than the $ G_{0} $ and $ G_{25} $ groups (P = 0.005). Conclusions For pregnant women with high-normal thyroid stimulating hormone levels and thyroid peroxidase antibodies positive during the first half of pregnancy, supplementation with 50 µg levothyroxine was more effective in improving their blood lipid status and gastrointestinal symptoms, reducing the incidence of SIBO and premature rupture of membranes, and before $ 11^{+2} $ weeks, TPOAb ≥ 117 IU/mL proved more beneficial in mitigating the risk of spontaneous abortion..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Lipids in health and disease - 23(2024), 1 vom: 10. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tian, Xin [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
Levothyroxine |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12944-024-02099-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055483569 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055483569 | ||
| 003 | DE-627 | ||
| 005 | 20240411064706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12944-024-02099-9 |2 doi | |
| 035 | |a (DE-627)SPR055483569 | ||
| 035 | |a (SPR)s12944-024-02099-9-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |a 570 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Tian, Xin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluation of the therapeutic efficacy of different doses of LT4 in pregnant women with high-normal TSH levels and TPOAb positivity in the first half of pregnancy |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background The objective was to investigate the efficacy of different doses of levothyroxine therapy among pregnant women exhibiting high-normal thyroid stimulating hormone levels and positive thyroid peroxidase antibodies throughout the first half of pregnancy. Methods Pregnant women exhibiting high-normal thyroid stimulating hormone levels and thyroid peroxidase antibodies positivity throughout the initial half of pregnancy were selected from January 2021 to September 2023. Based on the different doses of levothyroxine, the pregnant women were categorized into the nonintervention group ($ G_{0} $, 122 women), 25 µg levothyroxine intervention group ($ G_{25} $, 69 women), and 50 µg levothyroxine intervention group ($ G_{50} $, 58 women). Serum parameters, gastrointestinal symptoms, small intestinal bacterial overgrowth (SIBO), maternal and neonatal outcomes were compared after the intervention among the three groups. Results After the intervention, in the $ G_{25} $ and $ G_{50} $ groups, the thyroid stimulating hormone, triglyceride and low-density lipoprotein levels were notably less in contrast to those in the $ G_{0} $ group (P < 0.05). The rates of abdominal distension and SIBO in the $ G_{25} $ and $ G_{50} $ groups were notably lower in contrast to the $ G_{0} $ group (P = 0.043 and 0.040, respectively). The $ G_{50} $ group had a lower rate of spontaneous abortion and premature membrane rupture than the $ G_{0} $ group (P = 0.01 and 0.015, respectively). Before $ 11^{+ 2} $ weeks of gestation and at thyroid peroxidase antibodies levels ≥ 117 IU/mL, in contrast to the $ G_{0} $ group, the $ G_{50} $ group experienced a decreased rate of spontaneous abortion (P = 0.008). The $ G_{50} $ group had significantly higher newborn weight than the $ G_{0} $ group (P = 0.014), as well as a notably longer newborn length than the $ G_{0} $ and $ G_{25} $ groups (P = 0.005). Conclusions For pregnant women with high-normal thyroid stimulating hormone levels and thyroid peroxidase antibodies positive during the first half of pregnancy, supplementation with 50 µg levothyroxine was more effective in improving their blood lipid status and gastrointestinal symptoms, reducing the incidence of SIBO and premature rupture of membranes, and before $ 11^{+2} $ weeks, TPOAb ≥ 117 IU/mL proved more beneficial in mitigating the risk of spontaneous abortion. | ||
| 650 | 4 | |a Levothyroxine |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Thyroid stimulating hormone |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Thyroid peroxidase antibodies |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Lipid |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SIBO |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Pregnancy outcome |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Xu, Yajuan |e verfasserin |4 aut | |
| 700 | 1 | |a Ban, Yanjie |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Dong |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Lulu |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Zongzong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Miao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Chenchen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yixin |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Pengkun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lipids in health and disease |d BioMed Central, 2002 |g 23(2024), 1 vom: 10. Apr. |w (DE-627)SPR029118360 |w (DE-600)2091381-3 |x 1476-511X |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2024 |g number:1 |g day:10 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12944-024-02099-9 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 23 |j 2024 |e 1 |b 10 |c 04 | ||